Iovance Biotherapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, May 5, 2020
April 27, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Announces H. Lee Moffitt Cancer Center to Present Lung Cancer Clinical Data at American Association for Cancer Research (AACR) Virtual Annual Meeting 2020
April 13, 2020 17:14 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics to Present at Upcoming Conferences
March 02, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
February 25, 2020 16:01 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies...
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
February 19, 2020 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
February 12, 2020 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
January 15, 2020 08:00 ET
|
Iovance Biotherapeutics, Inc.
- Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage...
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
January 12, 2020 16:30 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
January 12, 2020 16:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer...
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December
December 02, 2019 07:00 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...